- Detail & Program Access
- Overview & Objectives
- Credit Eligibility
- Program Materials
- Funding Support
This program will cover the key clinical trial findings and their implications from AHA 2023. This program is intended for cardiovascular specialists and primary care physicians from across Canada.
SELECT – Semaglutide in patients with CAD and obesity: a new era in CV risk management?
ORBITA-2 – Does coronary stenting improve CV
outcomes in stable angina?
AZALEA – Is a factor XI inhibitor truly safer than
rivaroxaban in atrial fibrillation?
ARTESIA/NOAH-AFNET 6 – Do we need to
anticoagulate patients with subclinical atrial
Following participation in this program, participants will be able to:
- Identify the clinical implications of the new data presented at AHA 2023
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice
The OnDemand recording of this live program is NOT accredited.
Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.
Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio.
This program was developed by the Canadian Collaborative Research Network, a not-for-profit physician organization. A PDF copy of the slides from this program is available for CCRN members of the CCRN website. Visit www.ccrnmd.com/resources to download the materials.
This program was developed by the Canadian Collaborative Research Network and received an unrestricted educational grant from Novo Nordisk and Anthos Therapeutics.
Just before you start
Please enter the password to continue.
This program requires registration and login.Register/Login